FY2025 Earnings Estimate for DVAX Issued By William Blair

Dynavax Technologies Corporation (NASDAQ:DVAX) – Equities research analysts at William Blair cut their FY2025 earnings estimates for shares of Dynavax Technologies in a research report issued to clients and investors on Thursday, November 6th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $0.19 for the year, down from their prior forecast of $0.23. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies’ Q4 2025 earnings at ($0.05) EPS.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The firm had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million.

DVAX has been the topic of a number of other research reports. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Dynavax Technologies in a research note on Friday, August 22nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Trading Up 2.1%

Shares of NASDAQ DVAX opened at $11.27 on Monday. Dynavax Technologies has a twelve month low of $9.20 and a twelve month high of $14.63. The firm has a market cap of $1.32 billion, a PE ratio of -24.50 and a beta of 1.09. The business has a fifty day simple moving average of $10.06 and a two-hundred day simple moving average of $10.29. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Insider Activity at Dynavax Technologies

In other news, Director Scott Dunseth Myers purchased 3,800 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average cost of $10.82 per share, with a total value of $41,116.00. Following the completion of the acquisition, the director owned 35,004 shares of the company’s stock, valued at approximately $378,743.28. This represents a 12.18% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds have recently made changes to their positions in DVAX. Profund Advisors LLC boosted its holdings in Dynavax Technologies by 2.7% in the 3rd quarter. Profund Advisors LLC now owns 38,380 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 995 shares during the last quarter. Choreo LLC raised its position in shares of Dynavax Technologies by 3.2% during the 1st quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 1,065 shares during the period. Osaic Holdings Inc. lifted its holdings in Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,226 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Dynavax Technologies by 4.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company’s stock worth $401,000 after acquiring an additional 1,453 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Dynavax Technologies by 1.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after acquiring an additional 1,625 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.